Chiesi Global Rare Diseases Announces Presentations on Lysos

Results from the clinical development programme developed with Protalix BioTherapeutics evaluating pegunigalsidase alfa (PRX-102) an investigational enzyme...

Related Keywords

Germany , United States , United Kingdom , Italy , China , Udine , Friuli Venezia Giulia , Sweden , Canada , France , French , Alpha Mannosidosis , Etoile Alpha , Uma Ramaswami , Chiesi Farmaceutici , Nathalie Guffon , Giacomo Chiesi , Maurizio Scarpa , B Corp , Group Chiesi , Lisbon North Hospital Center Portugal , Protalix Ltd , Berry Company Public Relations , Protalix Biotherapeutics , Chiesi Group , United Nations Sustainable Development Goals Sdgs , Regional Reference Centre , Rare Diseases , Udine University Hospital , Global Rare Diseases , Inborn Errors , Annual Symposium , Royal Free Hospital , Preference Centre , Inherited Metabolic Diseases , Enfant Hospital , Patricio Ricardo , Terra Aguiar , Lisbon North Hospital Center , Chiesi Global Rare , United Nations Sustainable Development Goals , French Etoile Alpha , Fabry Disease , Pegunigalsidase Alfa , Velmanase Alfa , Benefit Corporation , Global Rare , Chiesi Global Rare Diseases , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,